Jim Cramer Calls Natera a Promising Story as Revenue Forecast Rises
Jim Cramer praised Natera’s precision medicine platform, urging investors to wait for a pullback. Natera reported Q2 revenue of $752.8 million, up 37.7% year over year, with oncology test volumes rising 57.2% and gross margin reaching 64.5%. Management raised its 2026 revenue forecast by $100 million and projected positive cash flow in 2026, while the company remains unprofitable.